文献速递消化道肿瘤放疗放疗物理与技术

骨髓和脾脏照射在食管癌放化疗期间急性血液学毒性发生中的作用

The role of bone marrow and spleen irradiation in the development of acute hematologic toxicity during chemoradiation for esophageal cancer.
PubMed 文献 · Adv Radiat Oncol · 2018-02-21

该研究分析60例接受术前或根治性同步放化疗的远端食管或胃食管交界癌患者,计算脾脏、胸椎和后肋的剂量学参数,主要终点为≥3级血液学毒性。多因素分析显示较高的脾脏V5-V20与较低的HT3+风险相关(V10每增加10 cm3,OR为0.83,P=0.013),放疗后脾脏体积下降幅度越大与HT3+风险越低独立相关(每下降1%,OR为0.93,P=0.014),胸椎剂量学参数与HT3+无显著关联。

要点

  • 60例食管癌放化疗患者中21例(35%)发生≥3级血液学毒性,包括18例白细胞减少和5例血小板减少。
  • 多因素分析显示脾脏V5-V20较高与HT3+风险较低相关(V10每增加10 cm3,OR为0.83,P=0.013)。
  • 放疗后脾脏体积下降幅度较大与HT3+风险较低独立相关(每下降1%,OR为0.93,P=0.014)。

核心结论

  • 放疗后脾脏体积下降幅度较大和较高的脾脏V5-V20与严重血液学毒性风险较低独立相关。
  • 脾脏照射可能减轻放化疗相关的白细胞减少。

研究设计与样本

  • 分析60例接受术前或根治性同步放化疗的远端食管或胃食管交界癌患者。
  • 计算脾脏、胸椎和后肋的剂量学和体积学参数。
  • 主要终点为≥3级血液学毒性(HT3+),采用逻辑回归和线性回归模型评估关联。

主要发现

  • 21例患者(35%)发生HT3+,包括18例白细胞减少和5例血小板减少。
  • 多因素分析显示较高的脾脏V5-V20与较低的HT3+风险相关(V10每增加10 cm3,OR为0.83,P=0.013)。
  • 放疗后观察到脾脏体积剂量依赖性下降,下降幅度较大与HT3+风险较低独立相关(每下降1%,OR为0.93,P=0.014)。
  • 胸椎剂量学参数与HT3+无显著关联。

关键数值与推荐

  • HT3+定义为≥3级血液学毒性。
  • 脾脏V10每增加10 cm3,HT3+的OR为0.83(P=0.013)。
  • 脾脏体积每下降1%,HT3+的OR为0.93(P=0.014)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to determine the impact of splenic and thoracic bone marrow irradiation on hematologic toxicity in the setting of chemoradiation therapy for esophageal cancer. METHODS AND MATERIALS: We analyzed 60 patients with carcinoma of the distal esophagus or gastroesophageal junction who received concurrent chemoradiation in the preoperative or definitive setting. Dosimetric and volumetric parameters were calculated for the spleen, thoracic spine, and posterior ribs. The primary endpoint was grade ≥3 hematologic toxicity (HT3+). Associations were assessed using logistic and linear regression models. RESULTS: Twenty-one patients (35%) experienced HT3+, including 18 patients with leukopenia and 5 with thrombocytopenia. Higher spleen V5-V20 was correlated with a lower risk of HT3+ on multivariable analysis (odds ratio: 0.83 per 10 cm3 increase in V10; P = .013). A dose-dependent decrease in spleen volume was observed after radiation therapy, and a greater decrease was independently associated with a lower risk of HT3+ (odds ratio: 0.93 per 1% volume decrease; P = .014). Dosimetric parameters of the thoracic spine were not significantly associated with HT3+. CONCLUSIONS: A greater decrease in spleen size after radiation therapy and a higher spleen V5-V20 were independently associated with a lower risk of severe hematologic toxicity. Splenic irradiation may mitigate leukopenia associated with chemoradiation therapy.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chin AL, Aggarwal S, Pradhan P, et al. The role of bone marrow and spleen irradiation in the development of acute hematologic toxicity during chemoradiation for esophageal cancer. Adv Radiat Oncol. 2018. PMID: 30202799. doi:10.1016/j.adro.2018.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。